Skip to main content

For LDL-C reduction in patients with primary hyperlipidemia along with diet and statin therapy.1

LEQVIO® (inclisiran) injection 284 mg/1.5 mL

The best therapy is the one patients actually take


Be confident your patients have received their dose with HCP-administered LEQVIO® — the only twice-yearly* LDL-C lowering therapy.

Are your patients ready to start LEQVIO? Find coverage in your area and fill out the Patient Start form to begin.

*After 2 initial doses and taken with statin therapy.

HCP, health care provider; LDL-C, low-density lipoprotein cholesterol; mAbs, monoclonal antibodies; PCSK9, proprotein convertase subtilisin/kexin type 9.
Reference: 1. Leqvio. Prescribing information. Novartis Pharmaceuticals Corp.